瘤微环境中疗法耐药性的机制:基于抗体阵列的细胞因子概况分析的见解
Rochelle Wickramasekara1, Valerie Jones1, Yating Zhao2
1RayBiotech Life Inc., Peachtree Corners, Georgia 30097, USA.
概括
固体瘤的耐疗性是由瘤微环境 (TME) 驱动的. 在TME中发出细胞因子信号,促进癌细胞存活和免疫逃避,导致治疗失败.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 免疫学 免疫学 免疫学
背景情况:
- 固体瘤的耐治疗性是癌症死亡的主要原因.
- 瘤微环境 (TME) 涉及结构细胞和免疫细胞,显著驱动非遗传性耐药性.
- 通过细胞因子,细胞接触和TME组件ECM重塑的细胞外部信号传递促进瘤存活和免疫逃避.
研究的目的:
- 审查TME内部的细胞因子介导的信号机制,有助于抵抗各种癌症疗法.
- 要突出基于抗体阵列的多重蛋白质基因分析在理解这些抗性机制中的作用.
主要方法:
- 对现有文献的综述,重点关注TME中细胞因子信号传递和治疗耐药性.
- 分析使用基于抗体阵列的多重蛋白质基因分析的研究.
- 检查针对耐药性途径的临床研究.
主要成果:
- 在瘤类型中发现的复发性细胞因子和生长因子信号通路 (例如IL-6/STAT3,CXCL12/CXCR4,HGF/c-MET) 通过近和自信号驱动抗性.
- 干细胞和免疫细胞利用这些途径来支持瘤的生存,免疫抑制和治疗逃避.
- 耐药机制因治疗方式和细胞环境而异;途径冗余和生物环境影响临床反应.
结论:
- 在TME内由细胞因子驱动的信号传输是治疗耐药性的核心.
- 蛋白质分析研究为TME介导的抗性途径提供了机械的洞察力.
- 需要进一步的临床研究来优化这些途径的向,以改善患者的治疗结果.
相关概念视频
01:27Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
02:17The Tumor Microenvironment
7.9K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.9K
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
01:27Cytotoxic T Cells-mediated Immune Response
7.6K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.6K